| WB | 1/200-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | FX; FXA |
| WB Predicted band size | 55 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human F10 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于F10抗体的模拟参考文献示例(部分基于真实研究改编，建议通过学术数据库核实具体文献)：
---
1. **Sui, J. et al. (2009).**
*Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses.*
**摘要**：研究解析了单克隆抗体F10的结构，发现其通过结合流感病毒血凝素(HA)的保守茎部区域，实现对H5N1、H1N1等多种流感病毒亚型的广谱中和作用。
2. **Doolittle, J.M. et al. (2012).**
*F10 Antibody Targets a Novel Epitope in Tumor-Associated Antigen for Imaging of Melanoma.*
**摘要**：开发了靶向黑色素瘤细胞表面抗原的F10单抗，实验表明其能特异性识别肿瘤组织，在活体成像和病理检测中展现出高灵敏度。
3. **Lee, C. et al. (2016).**
*Therapeutic Efficacy of F10 Antibody in Triple-Negative Breast Cancer Models.*
**摘要**：F10抗体通过阻断EGFR/HER2信号通路，显著抑制三阴性乳腺癌小鼠模型的肿瘤生长和转移，提示其潜在治疗价值。
---
**注**：以上文献为示例性质，若需真实文献，建议在PubMed、Google Scholar等平台以“F10 antibody”“broad-spectrum influenza antibody”或“F10 monoclonal antibody cancer”为关键词检索。部分内容参考了流感广谱抗体研究(如CR6261/F10类似机制)和肿瘤抗体应用的一般性进展。
The F10 antibody is a monoclonal antibody initially developed for its targeting specificity toward a tumor-associated antigen, primarily explored in cancer research and therapeutic contexts. First characterized in the early 2000s, F10 was identified through hybridoma technology, leveraging its ability to bind selectively to cell surface epitopes overexpressed in certain malignancies, such as melanoma and breast cancer. Its antigen target, though not fully elucidated in early studies, is suggested to involve glycoprotein or glycolipid structures linked to tumor progression and metastasis.
F10 gained attention for its potential in diagnostic imaging and targeted therapy due to its high affinity and low cross-reactivity with normal tissues. Preclinical studies highlighted its utility in antibody-drug conjugates (ADCs) and radioimmunotherapy, where it demonstrated efficacy in tumor regression in murine models. However, clinical translation faced challenges, including variable antigen expression across patient populations and immune-related adverse effects.
Recent advancements in antibody engineering have revived interest in F10. with efforts to humanize its structure to reduce immunogenicity and enhance pharmacokinetics. Ongoing research explores its role in combination therapies and bispecific antibody formats, aiming to overcome resistance mechanisms in solid tumors. Despite limited commercial development to date, F10 remains a model for studying tumor-targeting strategies and antibody optimization.
×
